Published in
American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(32), p. TPS3664-TPS3664, 2014
DOI: 10.1200/jco.2014.32.15_suppl.tps3664
Links
Tools
Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.
Journal article published in 2014 by
Lisa Salvatore 
,
Fotios Loupakis,
Chiara Cremolini,
Gianluca Masi,
Francesca Bergamo,
Antonella Galiano,
Vittorina Zagonel,
Laura Ferrari,
Elena Ongaro,
Giovanni Cardellino,
Lorenzo Marcucci,
Sara Lucchesi,
Maria Banzi,
Andrea Ciarlo,
Emanuela Miraglio
and other authors.
,
Fotios Loupakis,
Chiara Cremolini,
Gianluca Masi,
Francesca Bergamo,
Antonella Galiano,
Vittorina Zagonel,
Laura Ferrari,
Elena Ongaro,
Giovanni Cardellino,
Lorenzo Marcucci,
Sara Lucchesi,
Maria Banzi,
Andrea Ciarlo,
Emanuela Miraglio
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 